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Paradoxic Elevation of Fibrinopeptide A After Streptokinase: Evidence
for Continued Thrombosis Despite Intense Fibrinolysis
PAUL R. EISENBERG , MD, MPH, FACe, LAURENCE A. SHERMAN, MD,
ALLAN S. JAFFE, MD, FAce
St . Louis, Missouri
Elevated levels of fibrinopeptide A, a marker of throm-
bin activity associated with acute myocardial infarction,
have been found to decrease after administration of
streptokinase when reperfusion occurs. In contrast, in
patients without reperfusion and those with reocclusion
after streptokinase therapy, fibrinopeptide A remains
elevated. In the present study early serial measurements
of fibrinopeptide A were used to further characterize
this paradoxic increase in thrombin activity after strep-
tokinase and to characterize its response to heparin.
In 19 patients with acute myocardial infarction fi-
brinopeptide A was elevated to 82.3 ± 43.5 ng/ml (mean
Early recanalization of occluded coronary arteries in patients
with acute myocardial infarction after admini stration of fi-
brinolytic agents has been shown to reduce the extent of
myocardial necrosis and to improve survival (1-5) . Al-
though the induction of intense fibrinolysis is an essential
determinant of the success of therapy , the need for inhibition
of thrombosis also is an important independent factor (6).
In previous studies (6), elevated plasma levels of fibrino-
peptide A, a small peptide released by the action of thrombin
from fibrinogen (7), observed early after acute myocardial
infarction . decreased after admini stration of streptokinase
when recanalization occurred . In contrast, in patient s in
whom coronary occlu sion persisted or recurred . fibrinop ep-
tide A remained increased up to 4 hours after adm inistration
of streptokinase , indicative of persistent thrombosis despite
the presence of a profound lytic state (6) . Thu s. in addition
to inducing thrombolysis , in some patients streptokinase
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± SE) before therapy. Thirty minutes after the initiation
of streptokinase, fibrinopeptide A increased to 300.1 ±
117.4 ng/ml (p < 0.01), consistent with extensive throm-
bin activity. Fibrinopeptide A remained elevated until
15 minutes after a heparin bolus injection when levels
decreased to 15% of the poststreptokinase value (49.2
± 13.3 ng/ml)(p < 0.001). These data document a prompt
paradoxic increase in thrombin activity after adminis-
tration of streptokinase that may be responsible for fail-
ure of therapy in some patients.
(J Am Call Cardiol 1987;/0:527-9)
appeared to concomitantly increase the tendency to throm -
bosis . In the present study earlier measurements of fibri-
nopeptide A were utilized to define the incidence. time
course and progression of this paradoxic response to strep-
tokinase and to characterize its response to heparin .
Methods
Selection of the patients and treatment. We studied
19 patients who received streptokinase within 8 hours of
the onset of symptoms. All had 2: I mm of ST segment
elevation in two contiguous leads and were < 76 years of
age . Patient s were excluded if they had active bleed ing , a
history of a cerebrovasc ular acc ident within the preceding
2 month s, active malignancy. a disorder of hemostasis, se-
verely limited venou s access. recent invasive procedures or
severe trauma (including cardi opulmonary resuscitation). or
if they were recei ving coumadin , Once informed con sent
was obtained . 750. 000 units of streptokinase was adm in-
istered as an intravenous infusion over I hour. After the
streptokinase infusion a 50 U/kg bolus of heparin was ad-
ministered and an infusion of heparin ( I ,000 U/h) initiated .
In general. all other medicines were discontinued and only
lidocaine or intravenous nitroglycer in was administered .
Acquisition of plasma samples. All samples were ob-
tained by specially trained techni cians initially by meticu-
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Table 1. Characteristics of 19 Patients
Age Gender Locus of Infarction
No. (yr) (male/female) (anterior/inferior)
All patients 19 62.0 ± 2.8 11/8 10/9
Recanalized* II 61.5±4.1 6/5 6/5
Did not recanalize* 8 63.2 ± 3.8 5/3 4/4
*The differences between groups were not significant (p > 0.05).
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lous venipuncture and after streptokinase through an 18
gauge heparin lock. Samples were obtained before, during
and immediately after streptokinase infusion and then 15
and 60 minutes after the heparin bolus injection. After each
sample was obtained, the heparin lock was flushed with 3
ml of 100 Il/rnl heparin-saline solution. Blood was drawn
into a precooled sample tube containing ethylenediamine-
tetraacetic acid, aprotinin and 0 phenylalanyl-l-prolyl-l-
arginine chloromethyl ketone, a thrombin inhibitor (8). The
sample was rapidly cooled to 4°C, and centrifuged at 1,500
g for 30 minutes to separate the plasma. Plasma was stored
at - 20°C for no more than 24 hours and then at - 70°C
until it was assayed. A log was kept on each sample drawn
to prospectively identify any difficulties with sample ac-
quisition or processing.
Assay for fibrinopeptide A. Fibrinopeptide A was
measured by radioimmunoassay after bentonite adsorption
of the plasma to remove fibrinogen (Mallinckrodt, Inc) (7,9).
In our laboratory the detectability of this assay is 1 ng/ml
and the upper limit of normal is 2.0 ng/ml (10). The in-
traassay variability is 5.7 ± 0.7%. The fibrinopeptide A
assay specificity was confirmed in a subset of samples with
an antiserum (II) specific for the carboxyterminal end of
fibrinopeptide A which excludes cross-reactivity with other
fibrinogen fragments that contain fibrinopeptide A (kindly
performed by Jeffrey Weitz, MD).
Determination of recanalization. The presence or ab-
sence of coronary recanalization was determined by two
investigators who did not know the values of fibrinopeptide
A. Criteria for recanalization included sudden resolution of
ST segment elevation with development of Q waves on the
electrocardiogram (ECG), sudden relief of chest pain, ven-
tricular arrhythmias indicative of reperfusion and a time to
peak plasma creatine kinase activity of < 12 hours from the
onset of therapy. Coronary angiography performed in 64%
of patients with recanalization and 38% without confirmed
the initial noninvasive classification in each case.
Statistical methods. The data are expressed as mean ±
SE. The data for fibrinopeptide A were normalized with a
log transformation before analysis with paired t tests.
Results
Recanalization. Of the 19 patients with acute myo-
cardial infarction treated with streptokinase, 14 (74%) were
treated within 5 hours (mean 4.1 ± 0.4) of the onset of
symptoms (Table I). A Q wave infarction evolved in all
patients. Eleven patients subsequently exhibited recanali-
zation and in eight reperfusion was not achieved. There was
a trend for patients in whom recanalization failed to be
treated later than those in whom it was successful (4.7 ±
0.6 versus 3.7 ± 0.5 hours, P = NS). Induction of a state
of systemic plasmin activation was evident in all patients
by a 67% decrease in mean fibrinogen (365 ± 39 mg/dl
before to 120 ± 18 mg/dl after streptokinase). Fibrin(ogen)
degradation products increased to 325 ± 84 1Lg/m\.
Response of fibrinopeptide A. On admission, fibri-
nopeptide A was elevated in all patients to a mean of 82.3
± 43.5 ng/m\. Within 30 minutes of the start of the strep-
tokinase infusion, fibrinopeptide A increased by 366% to
300. I ± 117.4 ng/rnl, indicative of increased action of
thrombin on fibrinogen (p < 0.01 compared with baseline)
(Fig. 1). Fibrinopeptide A remained elevated at 60 minutes
when the infusion was completed (318 ± 128.3 ng/ml).
Fifteen minutes after the heparin bolus the marked elevation
of fibrinopeptide A had decreased to 15% of the poststrep-
tokinase value to 49.2 ± 13.3 ng/ml (p < 0.001) and after
I hour still further to 16.5 ± 3.4 ng/m\. The marked initial
increase in thrombin activity after streptokinase (at 30 and
60 minutes) was observed in all but three patients in whom
no change in fibrinopeptide A occurred, a response similar
to that of patients without infarction or those with a non-Q
Figure 1. Response of fibrinopeptide A (FPA) to streptokinase
(SK) and heparin (Hep) in 19 patients with acute myocardial in-
farction. Data points indicate the mean value ± SE at each time.
The fibrinopeptide A level is markedly elevated immediately after
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wave infarction (10). Each of these patients had an admis-
sion fibrinopeptide A level that was not markedly elevated
« 8,0 ng/rnl). The initial response of fibrinopeptide A to
streptokinase was similar in patients with and without re-
canalization. However, after administration of heparin a
trend toward more persistent elevation of fibrinopeptide A
was noted in patients in whom recanalization did not occur
(12.3 ± 2.4 ng/ml in those with recanalization compared
with 22.2 ± 7.1 ng/ml in those without).
Discussion
The prompt and marked elevation of fibrinopeptide A
found in 84% of the patients after administration of strep-
tokinase is consistent with the occurrence of extensive in-
travascular thrombin activity. This paradoxic increase in
thrombin activity suggests an unexpected enhancement of
thrombosis or a prothrombotic effect of streptokinase. Thus,
the marked thrombotic state associated with acute myo-
cardial infarction continues and may be exacerbated by
streptokinase. Strategies to inhibit the activation of thrombin
during thrombolysis are likely to improve the success of
therapy.
Potential mechanisms for persistent thrombin activity
after streptokinase. The mechanism for the marked un-
expected increase in thrombin activity after streptokinase
was not evaluated in this study. Lysing the thrombus itself
might lead to such activity. Experimental data (12) suggest
that there is release of thrombin from within the thrombus
when it lyses. It may also be that the underlying arterial
injury provides a continuing thrombogenic stimulus (13),
unmasked by clot lysis. Either mechanism could account
for the elevations of fibrinopeptide A observed. It is also
possible that streptokinase itself or the lytic state induced
may increase thrombin activity or decrease its inhibition.
Nonetheless, the increase in thrombin activity is not tran-
sient, judging from the persistent elevations observed de-
spite the short half-life of fibrinopeptide A (3 to 5 minutes).
The prompt response to heparin confirms that the elevations
of fibrinopeptide A are due to intravascular thrombin activity
(14) and suggests that inhibition of this prothrombotic re-
sponse is possible. Our data may provide the reason for
previous findings (15,16) that inhibition of recurrent throm-
bosis either by depletion of fibrinogen or by thrombin in-
hibition enhances the rate of clot dissolution after admin-
istration of fibrinolytic agents.
Clinical implications. From first principles, the fact that
thrombin activity and therefore initiation of thrombosis in-
creases after administration of a fibrinolytic agent such as
streptokinase is likely to influence the success of therapy.
Initially, the impact of this effect on the balance between
thrombosis and fibrinolysis in the coronary artery may be
limited by the intense early fibrinolytic response, perhaps
because of prompt lysis of fibrin I (17). However, as the
intensity of the fibrinolytic state wanes, the persistence of
thrombotic activity is associated with the failure of coronary
recanalization (6). Thus, it is likely that this unexpected
paradoxic increase in thrombin activity after streptokinase
affects the probability of coronary thrombolysis and, thus,
has important implications for the proper use of streptoki-
nase and of adjunctive therapy (such as heparin) in patients
with acute myocardial infarction.
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